Patients with acromegaly might not be at higher risk for dopamine agonist- induced impulse control disorders than those with prolactinomas

ÖZKAYA, Hande; Sahin, Serdar; Korkmaz, Ozge; DURCAN, Emre; Sahin, Humeyra; ÇELİK, Emir; POYRAZ, BURÇ; KADIOĞLU, Pınar

doi:10.1016/j.ghir.2020.101356

Patients with acromegaly might not be at higher risk for dopamine agonist- induced impulse control disorders than those with prolactinomas

Copy For Citation

ÖZKAYA H. M., Sahin S., Korkmaz O. P., DURCAN E., Sahin H. R., ÇELİK E., ...More

GROWTH HORMONE & IGF RESEARCH, vol.55, 2020 (SCI-Expanded)

Publication Type: Article / Article
Volume: 55
Publication Date: 2020
Doi Number: 10.1016/j.ghir.2020.101356
Journal Name: GROWTH HORMONE & IGF RESEARCH
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
Keywords: Acromegaly, Dopamine agonist, Impulse control disorder, Prevalence, NONFUNCTIONING PITUITARY-ADENOMAS, COMPULSIVE BEHAVIORS, PARKINSONS-DISEASE, SHORT-FORM, AGE, HYPERPROLACTINEMIA, ASSOCIATION, PERSONALITY, CABERGOLINE, THERAPY
Istanbul University Affiliated: Yes

Abstract

Objective: To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC).